Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

COSMO BIO CO LTD Lowers Consolidated Mid-year and Full-year Outlook for FY 2013


Friday, 19 Jul 2013 02:00am EDT 

COSMO BIO CO LTD announced that it has lowered the consolidated mid-year outlook for revenue from JPY 3,830 million to JPY 3,557 million, operating profit from JPY 327 million to JPY 247 million, ordinary profit from JPY 380 million to JPY 295 million, net profit from JPY 211 million to JPY 184 million and earning per share from JPY 35.59 to JPY 31.12 for the fiscal year ending December 31, 2013. The Company has also lowered the consolidated full-year outlook for revenue from JPY 7,530 million to JPY 7,250 million, operating profit from JPY 549 million to JPY 250 million, ordinary profit from JPY 636 million to JPY 403 million, net profit from JPY 364 million to JPY 303 million and earning per share from JPY 61.40 to JPY 51.11 for the fiscal year ending December 31, 2013. The negative outlook is mainly due to low performance of biochemical related research and development, and the impact of fluctuation of exchange rate. 

Latest Developments for Cosmo Bio Co Ltd

Company Quote

1725.0
27.0 +1.59%
11 Jul 2014